(HealthDay News) — The Supreme Court decision in Association for Molecular Pathology v. Myriad is not likely to have much immediate impact the practice of oncology, according to a special communication published online June 13 in the Journal of Clinical Oncology.

Kenneth Offit, M.D., M.P.H., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues reviewed previous court cases and gene patents, as well as earlier rulings in the course of this case.

The authors note that, for most common cancer susceptibility genes other than BRCA, which is at the center of this case, genetic testing is not restricted by exclusive patent enforcement. Isolated DNA patents are already becoming obsolete with the advent of next generation sequencing technologies.

Continue Reading

Additionally, methods patents based on DNA sequence have already been weakened by earlier rulings. Patents related to new drug development usually involve cellular methods and thus will not likely be impacted by this case.

“It is important that judicial and legislative actions in this area maximize genomic discovery while also ensuring patients’ access to personalized cancer care,” the authors write.

One author disclosed financial ties to the pharmaceutical industry.